Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02614261 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Galcanezumab in the Prevention of Chronic Migraine
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,117
- Enrollment target
NCT02614261: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT02614261 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,117 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02614261, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,117 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine.
Primary Outcome
MHD: A calendar day on which a migraine headache or probable migraine headache occurred. Overall mean is derived from the average of months 1 to 3 from mixed model repeated measures (MMRM) model. Least square(LS) Mean was calculated using MMRM model with treatment, pooled country, baseline medication overuse, concurrent prophylaxis use, month, treatment by month, baseline, and baseline by month as fixed effects.
Interventions
- DRUG Placebo
- DRUG Galcanezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,117 participants |
| Start Date | 2015-11-30 |
| Est. Completion | 2021-07-14 |
| Phase | Phase 3 |
What the finished NCT02614261 record still lists
NCT02614261 is an interventional study that assigns participants to a tested intervention. Its 1,117 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02614261 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02614261 about?
NCT02614261 is a clinical study titled "Evaluation of Galcanezumab in the Prevention of Chronic Migraine". The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine.
What is the current status of trial NCT02614261?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,117 participants. The study started on 2015-11-30. Estimated completion is 2021-07-14.
What interventions are being tested in trial NCT02614261?
The interventions under investigation include: Placebo (DRUG), Galcanezumab (DRUG).
Who is sponsoring clinical trial NCT02614261?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02614261's enrollment target sits among peer trials
1,117 251st of 2000 higher than 1,750 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02140255 · 1,120 participants · Phase 1
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
- NCT06618534 · 1,120 participants · Phase 2
Azithromycin for Meningococcal Carriage
- NCT07164131 · 1,120 participants · Phase 4
Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams
- NCT05691478 · 1,122 participants · Phase 2
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI